Robbins LLP Informs Investors of the Unicycive Therapeutics, Inc. Securities Class Action
Robbins LLP, a shareholder rights law firm, is soliciting investors for a securities class action filed against Unicycive Therapeutics on behalf of purchasers of UNCY securities between December 29, 2025 and June 29, 2026. The complaint alleges Unicycive misled investors by failing to disclose it had neither inspected nor audited its third-party manufacturing vendor's facility before claiming the vendor had resolved FDA deficiencies. The FDA issued a second Complete Response Letter on the resubmitted NDA for oxylanthanum carbonate in June 2026, citing the same manufacturing deficiencies flagged in its June 2025 CRL.
Key figures
- Prior crl date
- June 2025
- Stock drop usd
- 3.01
- Post drop close
- 4.69
- Stock drop date
- June 30, 2026
- Class period end
- June 29, 2026
- Class period start
- December 29, 2025
- Stock drop percent
- 39.1%
- Resubmitted nda date
- December 2025
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.